Summit Therapeutics
Summit Therapeutics
Explore linked clinical trials.31 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-10-08 | NCT05899608 | |
| Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 3 | 2026-10-06 | NCT07228832 | |
| Ivonescimab for the Treatment of Thymic Cancer | thymic carcinoma | Recruiting | Phase 2 | 2026-10-05 | NCT06980077 | |
| A Study of Ivonescimab in People With Endometrial and Cervical Cancers | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, cervix disorder, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Recruiting | Phase 2 | 2026-09-21 | NCT06925724 | |
| STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL) | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, adenocarcinoma, adrenal cortex disorder, adrenal cortex neoplasm, adrenal gland cancer, adrenal gland disorder, carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, neuroendocrine neoplasm, paraganglioma, pheochromocytoma, primitive neuroectodermal tumor | Not yet recruiting | Phase 2 | 2026-09-18 | NCT07743138 | |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-09-18 | NCT06767514 | |
| A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 | 2026-09-16 | NCT07619339 | |
| A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma | Neoplasms by Histologic Type, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma | Recruiting | Phase 2 / Phase 3 | 2026-09-11 | NCT07815665 | |
| Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, esophageal cancer, esophageal disorder, gastric cancer, gastric neoplasm, neoplasm, stomach disorder | Recruiting | Phase 2 | 2026-08-28 | NCT07070466 | |
| Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Recruiting | Phase 2 | 2026-08-28 | NCT07057791 | |
| Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients | Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, biliary tract cancer, biliary tract disorder, carcinoma, cholangiocarcinoma, epithelial neoplasm, neoplasm | Recruiting | Phase 2 | 2026-08-28 | NCT06529718 | |
| A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA) | Neoplasms by Histologic Type, adenocarcinoma, appendix adenocarcinoma, carcinoma, cystic, mucinous, and serous neoplasm, epithelial neoplasm, mucinous adenocarcinoma, neoplasm | Not yet recruiting | Phase 2 | 2026-08-27 | NCT07753824 | |
| A Study of Ivonescimab in People With Leiomyosarcoma | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, leiomyosarcoma, myomatous neoplasm, neoplasm, sarcoma | Recruiting | Phase 2 | 2026-08-27 | NCT07516925 | |
| Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, clear cell renal carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, renal cell carcinoma, urinary system disorder | Recruiting | Phase 2 | 2026-08-20 | NCT06940518 | |
| Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy | Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, adenoma, epithelial neoplasm, lung disorder, lung neoplasm, malignant mesothelioma, mesothelial neoplasm, mesothelioma, neoplasm, pleural neoplasm, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 | 2026-08-10 | NCT06840834 | |
| Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 2 | 2026-08-04 | NCT07017673 | |
| Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, colonic disorder, colorectal carcinoma, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, rectal disorder, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-08-03 | NCT07397338 | |
| Phase III Study of AK112 for NSCLC Patients | Non-Squamous Non-small Cell Lung Cancer | Active, not recruiting | Phase 3 | 2026-07-28 | NCT06396065 | |
| A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 1 / Phase 2 | 2026-07-21 | NCT06672575 | |
| Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 | 2026-07-15 | NCT07405190 | |
| A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-07-13 | NCT07535437 | |
| Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer | Advanced Head and Neck Squamous Cell Carcinoma; Resectable Head and Neck Squamous Cell Carcinoma; Stage II Head and Neck Cutaneous Squamous Cell Carcinoma; Stage III Head and Neck Cutaneous Squamous Cell Carcinoma; Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma | Recruiting | Phase 2 | 2026-06-26 | NCT07094685 | |
| Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma | skin squamous cell carcinoma | Recruiting | Phase 2 | 2026-06-11 | NCT06567314 | |
| Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Not yet recruiting | Phase 2 | 2026-06-04 | NCT07234877 | |
| Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Recruiting | Phase 3 | 2026-05-20 | NCT07264075 |